Mode
Text Size
Log in / Sign up
N/A N=466

Safety and Efficacy Study of Tendril MRI™ Leads in Standard Bradycardia Pacing Indication

Bradycardia

Enrolled (actual)
466
Serious AEs
37.3%
Results posted
Aug 2016
Primary outcome: Primary: Freedom From RA and RV Lead-related Complications — 97.19; 99.14 percentage of participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Abbott Medical Devices
Primary completion
Jun 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Freedom From RA and RV Lead-related Complications
97.19; 99.14

Summary

The purpose of this observational study is the assessment (safety and efficacy) of the St. Jude Medical Tendril MRI™ leads. The Tendril MRI™ leads are a full part of the Accent MRI™ System, consisting of Tendril MRI™ leads and Accent MRI™ pacemaker. The subject population includes patients with a standard bradycardia pacing indication.

Eligibility Criteria

Inclusion Criteria

  • Approved Class I or Class II indication per: European Society of Cardiology (ESC) guidelines for implantation of a dual chamber pacemaker or single chamber pacemaker, OR American College of Cardiology (ACC) / American Heart Association (AHA) / Heart Rhythm Society (HRS) guidelines for implantation of a dual chamber pacemaker or single chamber pacemaker
  • Require a new Accent MRI™ pacemaker and Tendril MRI™ lead (either initial implant or complete system change out with no abandoned devices).
  • Is ≥ 18 years of age.
  • Able to provide written informed consent prior to any investigational related procedure.
  • Willing and able to comply with the prescribed follow-up tests and schedule of evaluations.

Exclusion Criteria

  • Have an existing pacemaker or ICD (abandoned devices and/or leads are not allowed. A new pacemaker and lead or complete system change out is required for enrollment).
  • Have an existing active implanted medical device (e.g., Implantable Cardioverter Defibrillator (ICD), neurostimulator, etc.).
  • Have a non-MRI compatible device or material implant (e.g., intracranial aneurysm clip, non-MRI compatible devices or material, metals or alloys, etc.).
  • Have a lead extender, plug or adaptor.
  • Have a prosthetic tricuspid heart valve.
  • Are currently participating in another investigational device or drug investigation.
  • Are allergic to Dexamethasone sodium phosphate (DSP).
  • Are pregnant or planning to become pregnant during the duration of the study.
  • Have a life expectancy of less than 12 months from Screening due to any life-threatening condition
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01528150). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search